| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.15B | +28.9% |
| Gross profit | ¥0.02B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | +308.3% |
| Gross margin | 14.8% | Net margin 4.3% |
| Revenue Q/Q | +25.4% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.13B | 85.2% |
| R&D | ¥0.01B | 4.9% |
| SG&A | ¥0.00B | 2.8% |
| Tax & other | ¥0.00B | 0.4% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
新开源 ・ 华仁药业 ・ 向日葵 ・ 万讯自控 ・ 顺网科技 ・ 长盈精密 ・ 东方日升 ・ 瑞普生物 ・ 经纬辉开 ・ 阳谷华泰 ・ ST亚光 ・ *ST聆达
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies